BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

703 related articles for article (PubMed ID: 36161620)

  • 1. Evaluation of the frequency and intensity of COVID-19 in patients with ankylosing spondylitis under anti-TNF therapy.
    Türk SM; Öztürk Z; Karataş D; Erkorkmaz Ü; Gönüllü E
    Turk J Med Sci; 2022 Apr; 52(2):522-523. PubMed ID: 36161620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TNF-alpha inhibitors for ankylosing spondylitis.
    Maxwell LJ; Zochling J; Boonen A; Singh JA; Veras MM; Tanjong Ghogomu E; Benkhalti Jandu M; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2015 Apr; (4):CD005468. PubMed ID: 25887212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
    McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
    Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Effect of Tumor Necrosis Factor-Alpha Inhibitors on Uveitis in Patients with Ankylosing Spondylitis.
    Lee S; Park YJ; Lee JY
    J Korean Med Sci; 2019 Nov; 34(42):e278. PubMed ID: 31674159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of ankylosing spondylitis with TNF inhibitors does not have adverse effect on results of liver function tests: a longitudinal study.
    Capkin E; Karkucak M; Cosar AM; Ak E; Karaca A; Gokmen F; Budak BS; Tosun M
    Int J Rheum Dis; 2015 Jun; 18(5):548-52. PubMed ID: 24612551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ankylosing Spondylitis Response to TNF Inhibition Is Gender Specific: A 6-Year Cohort Study.
    Murray C; Fearon C; Dockery M; Moran D; Heffernan E; Fitzgerald O; Veale DJ; Harty L
    Ir Med J; 2018 Oct; 111(9):820. PubMed ID: 30556668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.
    Favalli EG; Pontikaki I; Becciolini A; Biggioggero M; Ughi N; Romano M; Crotti C; Gattinara M; Gerloni V; Marchesoni A; Meroni PL
    Clin Rheumatol; 2017 Aug; 36(8):1747-1755. PubMed ID: 28597133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficiency of adalimumab, etanercept and infliximab in ankylosing spondylitis in clinical practice.
    Escudero-Vilaplana V; Ramírez-Herráiz E; Alañón-Plaza E; Trovato-López N; García-Vicuña R; Carreño-Pérez L; Morell-Baladrón A; Sanjurjo-Sáez M
    Int J Clin Pharm; 2015 Oct; 37(5):808-14. PubMed ID: 25910480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and complication of COVID-19 in patients with ankylosing spondylitis (AS) and its relationship with TNF-a inhibitors.
    Movassaghi S; SeyedAlinaghi S; Rostamian A; Najafizadeh SR; Nezhadseifi E
    Immun Inflamm Dis; 2023 Jun; 11(6):e915. PubMed ID: 37382255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register.
    Lie E; Lindström U; Zverkova-Sandström T; Olsen IC; Forsblad-d'Elia H; Askling J; Kapetanovic MC; Kristensen LE; Jacobsson LTH
    Ann Rheum Dis; 2017 Sep; 76(9):1515-1521. PubMed ID: 28254789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PAPA Syndrome: Challenges in Achieving Long-Term Remission.
    Smajlović H; Prohić A
    Acta Dermatovenerol Croat; 2023 Nov; 31(2):106-109. PubMed ID: 38006373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The long-term persistence of tumor necrosis factor inhibitors in patients with moderate to severe immune-mediated rheumatic diseases: A nation-wide, population-based real-world study.
    Huang JY; Leong PY; Ker A; Chen HH; Wei JC
    Int J Rheum Dis; 2022 Nov; 25(11):1295-1305. PubMed ID: 35975402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.
    Schabert VF; Watson C; Joseph GJ; Iversen P; Burudpakdee C; Harrison DJ
    J Manag Care Pharm; 2013 Oct; 19(8):621-30. PubMed ID: 24074008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Formation and clearance of TNF-TNF inhibitor complexes during TNF inhibitor treatment.
    Berkhout LC; I'Ami MJ; Kruithof S; Vogelzang EH; Hooijberg F; Hart MHL; Bentlage AEH; Thomas D; Vermeire S; Vidarsson G; Ten Brinke A; Nurmohamed MT; Wolbink GJ; Rispens T
    Br J Pharmacol; 2024 Apr; 181(8):1165-1181. PubMed ID: 37859583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High BMI is associated with lower TNF-α inhibitor serum trough levels and higher disease activity in patients with axial spondyloarthritis.
    de Wolff L; Arends S; Brouwer E; Bootsma H; Spoorenberg A
    Arthritis Res Ther; 2023 Oct; 25(1):202. PubMed ID: 37848964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database.
    Wendling D; Joshi A; Reilly P; Jalundhwala YJ; Mittal M; Bao Y
    Curr Med Res Opin; 2014 Dec; 30(12):2515-21. PubMed ID: 25252590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Comparative Safety of TNF Inhibitors in Ankylosing Spondylitis-a Meta-Analysis Update of 14 Randomized Controlled Trials.
    Hou LQ; Jiang GX; Chen YF; Yang XM; Meng L; Xue M; Liu XG; Chen XC; Li X
    Clin Rev Allergy Immunol; 2018 Apr; 54(2):234-243. PubMed ID: 28717941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study.
    Pappas DA; St John G; Etzel CJ; Fiore S; Blachley T; Kimura T; Punekar R; Emeanuru K; Choi J; Boklage S; Kremer JM
    Ann Rheum Dis; 2021 Jan; 80(1):96-102. PubMed ID: 32719038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of anti-TNF on renal function in patients with ankylosing spondylitis: a prospective cohort study.
    Swart IAP; Visman IM; Heslinga M; van der Horst-Bruinsma IE; van Denderen JC; Nurmohamed MT
    Clin Rheumatol; 2022 Dec; 41(12):3747-3752. PubMed ID: 35962246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.